Another feat based on GN Corporations inter-disciplinary research cum translational initiative

May13, 2026

Paracrine effect of 2D cultured cells and successful engraftment of 3D Festigel® cultured autologous buccal epithelial cells through wound healing help cover the urethrotomy wound, thereby preventing recurrence of urethral stricture causing spongiofibrosis.

Please see details in the following article:

businesswire

Japanese healthcare technology company finds synergy with Indian market and Medinippon’s network

April 27, 2026

Medinippon provides services from market study, sales & marketing effort, and approval by Ministry of Health, Govt of India (CDSCO) for successful business launch by Create Medic Japan, a company listed in Tokyo stock exchange

Please see details in the following article:

Create Medic Launch Ceremony

The launch ceremony of Indian subsidiary of Create Medic, Japan in Chennai, 15th April 2026; Hon’ble Consul General of Japan Mr. Muneo Takahashi delivering the Chief Guest’s address;

In the pic L>R: Mr. Kousuke Suto, GM-Create Medic India, Prof. Shyamkumar N. Keshava, Dept. of Interventional Radiology, CMC, Vellore, Mr. Osamu Imazawa, President, Create Medic Japan, Mr. Katsuaki Yamane, MD, Create Medic India & Dr. Rajappa Senthilkumar, Director, MediNippon Healthcare.

In the pic L>R: Prof. Shyamkumar Keshava (Prof. of Radiology, CMC Vellore), Mr. Muneo Takahashi (Hon`ble Consul General of Japan, Chennai, India), Mr. Osamu Imazawa (President, Create Medic Co Ltd, Japan), Mr. Katsuaki Yamane (Managing Director, Create Medic Pvt Ltd, India), Mr. Kousuke Suto (Director, Create Medic Pvt Ltd, India), Prof. S. Arumugam (Head, Institute of Sports Sciences, Sri Ramachandra Institute of Higher Education, Chennai, India), Dr. Rajappa Senthilkumar (Director, Create Medic Pvt Ltd, India) 

Vietnam’s Role in Asian Medical Tourism; NCRM & GN Corporation spearhead tech-transfer

October 29, 2025

Colorectal cancer, Lung Cancer and Liver Cancer patients report longer survival and improved quality of life after AIET cell therapy using NK cells and T Cells, presented in NCRM NICHE annual conference.

Please see details in the following BiopharmaAPAC article:

BiopharmaAPAC

At International Conference in Yokohama, Japan

17 Aug 2024

Nichi BRITE Beta glucan administration resulted in enhancement of immunity followed by reduction in biomarkers of pancreatic cancer and that of its recurrence in patients undergoing surgical resection of malignant pancreatic tumor, which was presented at the ASCO® Breakthrough meeting in Yokohama, Japan.

IgA and CD209, markers of immunity enhanced while CA19-9, the marker of pancreatic cancer and CD44, that of cancer recurrence and severity, significantly reduced in patients who had Nichi BRITE, compared to the control group in the study by gastro-enterology surgeons and nutritional support team of Chikamori Hospital, Kochi, Japan.

Importantly, the mean survival improved after Nichi BRITE administration.

For further details, please visit our Businesswire press release.

At the MENA Conference on Rare DiData presented in IFPA 7^th World Psoriasis conference, in Stockholm, Sweden

04 July 2024

A breakthrough improvement in clinical signs and symptoms of Psoriasis Vulgaris proven by skin biopsy, following oral consumption of  Neu REFIX Beta glucan for 28 days in a clinical trial conducted by the team of Prof. J. Thadeus, Head, Dept. of Dermatology, Govt. Thoothukudi Medical College, taking technical advice from Japanese scientists was presented in the International Federation of Psoriasis Associations (IFPA) Conference; The 7^th World Conference of Psoriasis and Psoriatic Arthritis, held in June in Stockholm, Sweden. Prof. J. Suresh Durai, of Tirunelveli Medical College and Dr. Ichiro Miura of Obihiro Hospital, Hokkaido, Japan, meticulously evaluated the skin biopsy findings to confirm the improvement.

Psoriasis is a multi-factorial inflammatory skin disease that affects 2~3% of the total population.  About 20~30% of patients may progress to psoriatic arthritis, which affects the joints. The disease pathology being highly complex, and a definitive cure is not currently available, disease modifying treatments remain the mainstream of management. Based on the earlier reports by Japanese scientists in pre-clinical and clinical studies using Neu REFIX Beta glucans, Dr. Thadeus conducted this trial in 30 patients; 20 of them took Neu REFIX along with conventional therapies while the other 10 had only conventional therapies. In the study, 80% of the patients who consumed Neu REFIX showed improvements in their skin condition. Infiltration of lymphocytes in skin, the cause of skin lesions and inflammation were significantly reduced in them compared to those who had only conventional treatment. PASI Score, which is the gold standard for evaluating the clinical severity also reduced significantly in Neu REFIX group. Dr. Thadeus is planning to organize an International Seminar to commemorate the World Psoriasis Day in October where the findings will also be shared.

This journey started in 2009, has gathered evidence of safety of this allergen-free Neu REFIX compound in KK-Ay mice, SD rats, NASH and mdx mice models; clinical studies in healthy volunteers and Duchenne muscular Dystrophy (DMD) patients besides its efficacy as an anti-inflammatory, immunomodulating adjuvant along with beneficial gut microbiome reconstitution, is now a hope to Psoriasis patients, added the scientists.

Please visit the Hindu news from here.

11Aug2023

Japanese medical device manufactures, Create Medic Co Ltd launched their Cliny PEG kits in India ably supported by Medinippon Healthcare Pvt Ltd, a sister company of GN Corporation for market survey, promotion and CDSCO registration; More products such as microcatheters to be launched in the near future.

Please see the article Bio StartUps for further details.

06July 2023

June 30, Chennai; Japanese scientists, research collaborators to Nichi-in Centre for Regenerative Medicine (NCRM) have reported an increased yield of Beta 1,3-1,6 glucans in the produce, as an exo-polysaccharide by the yeast Aureobasidium Pullulans employing improvised culture methodology.

Please visit press release here.

N-163 strain of Aureobasidium Pullulans produced Beta 1,3-1,6 glucans (‘Neu REFIX‘) improved butyrate and beneficial gut microbiome relavent to anti-aging phenomemon in NASH mice models; The Hindu Business Line

Male urethral stricture, which increases after the age of 55, has been treated by endoscopic urethrotomy and dilatation or surgical urethroplasty using an oral mucosa patch, but both have been reported with recurrence. In a paper published in Stem Cell Reviews and Reports (https://doi.org/10.1007/s12015-022-10466-1), it is reported that Japanese urologists have succeeded in confirming the engraftment of transplanted cells on to the site of urethrotomy, using a new polymeric scaffold developed by Japanese scientists.

This engraftment on the open wound of urethrotomy is considered vital to prevent the recurrence of the stricture after the treatment, making this BEES-HAUS appealing to be taken as the first option as it gets validated in larger studies.

At the NCRM NICHE 2022 conference, co-sponsored by Edogawa Hospital and GN Corporation, Dr. Akio Horiguchi, a urologist specializing in the treatment of urethral stricture, reported on cell engraftment, and Dr. Dmitriy Nikolavsky (Upstate Medical University, New York), a clinician in the field of urethral stricture, lauded this achievement. Dr. Suryaprakash Vaddi (India) presented a clinical report of BEES-HAUS cell therapy in six patients.

Click here to read Business Wire’s press release on the presentation at NCRM NICHE 2022, the International Conference on Regenerative Medicine.